L-글루타민 관련 과민성 대장 증후군(IBS)
C 근거 소규모 연구에서의 근거는 제한적이지만, 일부 긍정적인 신호가 존재합니다.예비 RCT에서 글루타민(5g 1일 3회)이 감염후 IBS에서 장 투과성과 IBS-D 증상을 줄이는 것으로 시사됩니다. 유망하나 더 큰 규모의 시험이 필요합니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dl\u002Dglutamine\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
결론
예비 RCT에서 글루타민(5g 1일 3회)이 감염후 IBS에서 장 투과성과 IBS-D 증상을 줄이는 것으로 시사됩니다. 유망하나 더 큰 규모의 시험이 필요합니다.
Key Study Findings
Other
Unraveling the active ingredients and molecular mechanisms of Qinghua Changyan granule against irritable bowel syndrome …
Dose: None
vs: None
Outcome: IBS-D symptom relief via gut microbiota and glutamine …
효과: None
None
대상 집단: animal model of IBS with diarrhea
Other
n=25
4 weeks
Effect of probiotic administration of Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 …
Dose: Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917
vs: phosphate-buffered saline (PBS)
Outcome: visceral hypersensitivity (abdominal withdrawal reflex scores)
효과: None
p<0.05
대상 집단: female rats with water avoidance stress-induced IBS-D model
Other
n=62
[Study on activation mechanism of SGCs in representation along the distribution of stomach meridian in …
Dose: None
vs: Control group (no citrobacter)
Outcome: SGC activation in DRG segments
효과: None
P<0.05 to P<0.01
대상 집단: Male C57BL/6 mice (IBS-D model)
Review
Intestinal Barrier Impairment, Preservation, and Repair: An Update.
Dose: None
vs: None
Outcome: Intestinal barrier preservation and repair
효과: None
None
대상 집단: IBD and IBS patients (review)
Other
Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes.
Dose: None
vs: None
Outcome: Cholesterol levels
효과: None
None
대상 집단: Mouse model
In Vitro
Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability …
Dose: None
vs: None
Outcome: inflammation markers
효과: None
None
대상 집단: Mice
Key Statistics
2
연구
150
참여자
↑
Positive
C
등급
Referenced Papers
Fitoterapia
2026
1 인용
Journal of the …
2026
Zhongguo zhen jiu …
2025
Nutrients
2024
47 인용
Cannabis and cannabinoid …
2024
10 인용
International journal of …
2023
9 인용
Journal of gastroenterology
2022
23 인용
NeuroImage. Clinical
2022
8 인용
Digestion
2021
29 인용
Frontiers in nutrition
2021
17 인용
Medicine
2021
Nutrition research (New …
2020
42 인용
World journal of …
2020
11 인용
Gut
2019
148 인용
Metabolomics : Official …
2019
41 인용
Pain
2019
23 인용
Scientific reports
2019
14 인용
Gut
2019
5 인용
[Not Available].
RCT
Praxis
2018
Current opinion in …
2017
71 인용
JPEN. Journal of …
2016
44 인용
Gastroenterology
2015
17 인용
Frontline gastroenterology
2012
20 인용
The American journal …
2011
48 인용
Clinical nutrition (Edinburgh, …
2011
12 인용
MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome.
Other
Gut
2010
263 인용
Clinics (Sao Paulo, …
2010
47 인용
Zhong xi yi …
2009
6 인용
Journal of clinical …
2008
73 인용
Nutrition in clinical …
2008
42 인용
Journal of proteome …
2006
80 인용
Medycyna wieku rozwojowego
2004
1 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 5-15 g/day
- ibsdsupport:
- 5 g three times daily (15 g/day total)
- postexercisegut:
- 0.25-0.9 g/kg before intense exercise
- gutbarriersupport:
- 0.5 g/kg/day (approximately 30-40 g/day for adults)
상한량: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 | 4 weeks | Positive | 25 |
| None | -- | Mixed | 62 |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Negative | 75 |
권장 복용 시간: Between meals or before exercise; divide doses throughout the day
Safety & Side Effects
보고된 부작용
- ⚠ Mild gastrointestinal discomfort at high doses
- ⚠ Headache
- ⚠ Dizziness at very high doses
- ⚠ Potential glutamate excitotoxicity concerns in neurological conditions (theoretical)
알려진 상호작용
- ● Lactulose (glutamine may reduce the efficacy of lactulose for hepatic encephalopathy)
- ● Anti-seizure medications (glutamine converts to glutamate; theoretical concern)
- ● Chemotherapy agents (glutamine may protect cancer cells; discuss with oncologist)
일일 최대 섭취 허용량: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does L-글루타민 help with 과민성 대장 증후군(IBS)?
Based on 2 studies with 150 participants, there is limited but promising evidence that L-글루타민 may support 과민성 대장 증후군(IBS) management. Our evidence grade is C (Some Evidence).
How much L-글루타민 should I take for 과민성 대장 증후군(IBS)?
Studies have used various dosages. A commonly studied range is 5-15 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of L-글루타민?
Reported side effects may include Mild gastrointestinal discomfort at high doses, Headache, Dizziness at very high doses, Potential glutamate excitotoxicity concerns in neurological conditions (theoretical). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for L-글루타민 and 과민성 대장 증후군(IBS)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: 과민성 대장 증후군(IBS)
L-글루타민 다른 건강 상태에 대한 근거
References
- [1] Jiayu Yang et al.. Fitoterapia. 2026. Unraveling the active ingredients and molecular mechanisms of Qinghua Changyan granule against irritable bowel syndrome with diarrhea: Effects on gut … doi:10.1016/j.fitote.2025.106960 PubMed
- [2] Nazila Dardmeh et al.. J Sci Food Agric. 2026. Effect of probiotic administration of Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 on metabolic profiles in an … doi:10.1002/jsfa.70190 PubMed
- [3] Na Li et al.. Zhongguo Zhen Jiu. 2025. [Study on activation mechanism of SGCs in representation along the distribution of stomach meridian in IBS-D mice]. doi:10.13703/j.0255-2930.20241126-0001 PubMed
- [4] Ayah Matar et al.. Nutrients. 2024. Intestinal Barrier Impairment, Preservation, and Repair: An Update. doi:10.3390/nu16203494 PubMed
- [5] Mengxue He et al.. Cannabis Cannabinoid Res. 2024. Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes. doi:10.1089/can.2022.0331 PubMed
- [6] Ludovic D Langlois et al.. Int J Mol Sci. 2023. Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability in a Chronic-Restraint Stress Model. doi:10.3390/ijms24087220 PubMed
- [7] Yukari Tanaka et al.. J Gastroenterol. 2022. Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation. doi:10.1007/s00535-022-01888-2 PubMed
- [8] Nawroz Barazanji et al.. Neuroimage Clin. 2022. Irritable bowel syndrome in women: Association between decreased insular subregion volumes and gastrointestinal symptoms. doi:10.1016/j.nicl.2022.103128 PubMed
- [9] Min Li et al.. Digestion. 2021. Glutamine Blocks Interleukin-13-Induced Intestinal Epithelial Barrier Dysfunction. doi:10.1159/000502953 PubMed
- [10] Samira Rastgoo et al.. Front Nutr. 2021. Glutamine Supplementation Enhances the Effects of a Low FODMAP Diet in Irritable Bowel Syndrome Management. doi:10.3389/fnut.2021.746703 PubMed
- [11] Yong Zhang et al.. Medicine (Baltimore). 2021. To assess the effective and safety of compound glutamine entersoluble capsules in irritable bowel syndrome: A protocol for systematic review … doi:10.1097/MD.0000000000025098 PubMed
- [12] Karin Ried et al.. Nutr Res. 2020. Herbal formula improves upper and lower gastrointestinal symptoms and gut health in Australian adults with digestive disorders. doi:10.1016/j.nutres.2020.02.008 PubMed
- [13] Magdy El-Salhy. World J Gastroenterol. 2020. Possible role of intestinal stem cells in the pathophysiology of irritable bowel syndrome. doi:10.3748/wjg.v26.i13.1427 PubMed
- [14] QiQi Zhou et al.. Gut. 2019. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. doi:10.1136/gutjnl-2017-315136 PubMed
- [15] Mai Yamamoto et al.. Metabolomics. 2019. Metabolomics reveals elevated urinary excretion of collagen degradation and epithelial cell turnover products in irritable bowel syndrome patients. doi:10.1007/s11306-019-1543-0 PubMed
- [16] Olga Bednarska et al.. Pain. 2019. Reduced excitatory neurotransmitter levels in anterior insulae are associated with abdominal pain in irritable bowel syndrome. doi:10.1097/j.pain.0000000000001589 PubMed
- [17] Adriane Icenhour et al.. Sci Rep. 2019. Elucidating the putative link between prefrontal neurotransmission, functional connectivity, and affective symptoms in irritable bowel syndrome. doi:10.1038/s41598-019-50024-3 PubMed
- [18] Alexander Charles Ford et al.. Gut. 2019. Efficacy of glutamine in postinfection IBS. doi:10.1136/gutjnl-2018-317438 PubMed
- [19] Johann Steurer. Praxis (Bern 1994). 2018. [Not Available]. doi:10.1024/1661-8157/a003109 PubMed
- [20] Najate Achamrah et al.. Curr Opin Clin Nutr Metab Care. 2017. Glutamine and the regulation of intestinal permeability: from bench to bedside. doi:10.1097/MCO.0000000000000339 PubMed
- [21] Julien Bertrand et al.. JPEN J Parenter Enteral Nutr. 2016. Glutamine Restores Tight Junction Protein Claudin-1 Expression in Colonic Mucosa of Patients With Diarrhea-Predominant Irritable Bowel Syndrome. doi:10.1177/0148607115587330 PubMed
- [22] Moïse Coëffier et al.. Gastroenterology. 2015. Intestinal permeability in patients with diarrhea-predominant irritable bowel syndrome: is there a place for glutamine supplementation? doi:10.1053/j.gastro.2015.02.057 PubMed
- [23] Melissa A Smith et al.. Frontline Gastroenterol. 2012. Nutritional management of adults with inflammatory bowel disease: practical lessons from the available evidence. doi:10.1136/flgastro-2011-100032 PubMed
- [24] David M Niddam et al.. Am J Gastroenterol. 2011. Reduced hippocampal glutamate-glutamine levels in irritable bowel syndrome: preliminary findings using magnetic resonance spectroscopy. doi:10.1038/ajg.2011.120 PubMed
- [25] Khaly Mbodji et al.. Clin Nutr. 2011. Alanyl-glutamine restores maternal deprivation-induced TLR4 levels in a rat neonatal model. doi:10.1016/j.clnu.2011.04.002 PubMed
- [26] QiQi Zhou et al.. Gut. 2010. MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome. doi:10.1136/gut.2009.181834 PubMed
- [27] Jean Robert Rapin et al.. Clinics (Sao Paulo). 2010. Possible links between intestinal permeability and food processing: A potential therapeutic niche for glutamine. doi:10.1590/S1807-59322010000600012 PubMed
- [28] Wen-yan Gao et al.. Zhong Xi Yi Jie He Xue Bao. 2009. [Effects of Changjishu soft elastic capsule in treatment of diarrhea-predominant irritable bowel patients with liver-qi stagnation and spleen deficiency syndrome: … doi:10.3736/jcim20090303 PubMed
- [29] Angelo Andriulli et al.. J Clin Gastroenterol. 2008. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized … doi:10.1097/MCG.0b013e31817fadd6 PubMed
- [30] Arnold Wald et al.. Nutr Clin Pract. 2008. Behavioral and complementary approaches for the treatment of irritable bowel syndrome. doi:10.1177/0884533608318677 PubMed
- [31] Francois-Pierre J Martin et al.. J Proteome Res. 2006. Transgenomic metabolic interactions in a mouse disease model: interactions of Trichinella spiralis infection with dietary Lactobacillus paracasei supplementation. doi:10.1021/pr060157b PubMed
- [32] Barbara Kamińska et al.. Med Wieku Rozwoj. 2004. [Environmental factors in the etiopathology of inflammatory bowel syndrome]. PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.